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Hypermethylation of the CpG Island
Near the G4C2 Repeat in ALS with a C9orf72 Expansion
Zhengrui Xi,1 Lorne Zinman,2 Danielle Moreno,1 Jennifer Schymick,1 Yan Liang,1 Christine Sato,1
Yonglan Zheng,3 Mahdi Ghani,1 Samar Dib,1 Julia Keith,2 Janice Robertson,1 and Ekaterina Rogaeva1,4,*
The G4C2 repeat expansion inC9orf72 is themost common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD).We tested the hypothesis that the repeat expansion causes aberrant CpGmethylation near the G4C2 repeat, which
could be responsible for the downregulation of gene expression. We investigated the CpG methylation profile by two methods using
genomic DNA from the blood of individuals with ALS (37 expansion carriers and 64 noncarriers), normal controls (n ¼ 76), and family
members of 7 ALS probands with the expansion. We report that hypermethylation of the CpG island 50 of the G4C2 repeat is associated
with the presence of the expansion (p< 0.0001). A higher degree of methylation was significantly correlated with a shorter disease dura-
tion (p< 0.01), associatedwith familial ALS (p¼ 0.009) and segregated with the expansion in 7 investigated families. Notably, we did not
detect methylation for either normal or intermediate alleles (up to 43 repeats), bringing to question the current cutoff of 30 repeats for
pathological alleles. Our study raises several important questions for the future investigation of large data sets, such as whether the
degree of methylation corresponds to clinical presentation (ALS versus FTLD).Amyotrophic lateral sclerosis (ALS [MIM 612069]) and
frontotemporal lobar degeneration (FTLD [MIM 600274])
constitute a neurodegenerative syndrome, with individual
cases presenting along a clinico-pathological spectrum. In-
dividuals with FTLD exhibit primary dementia commonly
characterized by early behavioral and/or language
changes, whereas ALS is characterized by the degeneration
of motor neurons responsible for voluntary movements.
Both syndromes may occur within the same family or
the same person. The most common known genetic cause
of ALS and FTLD is the recently discovered noncoding
hexanucleotide (G4C2)n > 30 repeat expansion in the chro-
mosome 9 open reading frame 72 gene (C9orf72 [MIM
614260]),1,2 which accounts for 24%–37% of familial and
6%–7% of sporadic cases in whites.3 This discovery was
confirmed in multiple data sets, including ours;4–7 how-
ever, the disease mechanism related to the C9orf72 G4C2
repeat expansion remains unknown.
There are several hypotheses about the functional conse-
quences of the repeat expansion. The toxic gain-of-func-
tion model is related either to the sequestering of RNA
binding proteins by RNA foci consisting of pre-mRNA con-
taining the repeat expansion1 or to the non-ATG-initiated
translation from the repeat expansion in all reading frames
leading to the aggregation of dipeptide-repeat proteins in
neurons.8,9 Another model is a loss-of-function mecha-
nism (haploinsufficiency), supported by observations
that the expansion leads to ~50% reduction of C9orf72
mRNA in frontal cortex and lymphoblasts derived from
heterozygous mutation carriers.1,4 Finally, it is possible
that all three mechanisms contribute to the disease.
Here we tested the hypothesis that the expansion may
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The Amdownregulation of its mRNA, as was shown for different
C9orf72 transcripts in a few published expansion car-
riers.1,4 Notably, the G4C2 repeat is mapped to the
promoter region of the NM_018325.3 transcript, and
the promoter region of two other C9orf72 transcripts
(NM_001256054.1 and NM_145005.5) overlaps a CpG
island 50 of the repeat (Figure S1 available online). Cytosine
(C) methylation of CpG dinucleotides is an important
epigenetic modification10 that could lead to gene expres-
sion silencing as a result of hypermethylation of CpG
islands11,12 (defined as >200 bp regions with >50% CG
content and >0.6 ratio of observed to expected number
of CG-dinucleotides). Several genes with repeat expansions
are known to have aberrant CpG methylation leading to
downregulation of gene expression. For example, in indi-
viduals with Friedreich ataxia (MIM 229300), hypermethy-
lation was detected upstream of the GAA expansion in
intron 1 of FXN (MIM 606829), which leads to a deficit
of FXNmRNA in blood, heart, and brain.13–15 DNA hyper-
methylation is also caused by a CGG expansion in the 50
UTR of FMR1 (MIM 309550) responsible for fragile X
mental retardation syndrome (MIM 300624).16–18 More-
over, the CTG expansion in the 30 UTR of DMPK (MIM
605377) causes hypermethylation19 of the promoter of a
downstream gene, reducing its transcription.20–22
To gain new insight into the C9orf72 disease mecha-
nism, we investigated the CpGmethylation profile around
the G4C2 repeat by two methods using genomic DNA
collected from our well-characterized Canadian ALS cohort
and normal controls. Informed consent was obtained from
all participants in accordance with the ethical review
board. Study participants were diagnosed with ALS at the
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Table 1. Sample Characteristics
Blood Brain (Frontal Cortex)
ALS Exp ALS Nonexp Control ALS Exp Control
Number of samples 37 64 76 7 14
Age at sample collection 60.5 5 9.5 66.5 5 9.3 73.0 5 7.6 56.7 5 7.8 78.1 5 7.7
Age at onset 58.6 5 9.4 63.7 5 11.4 – 55.3 5 8.1 –
Female (frequency) 15 (0.41) 25 (0.39) 48 (0.63) 3 5
Family history ( frequency) 18 (0.49) 5 (0.08) – 5 –
Diagnosis ALS ( frequency) 32 (0.86) 54 (0.84) – 4 –
ALS-FTD ( frequency) 5 (0.14) 10 (0.16) – 3 –
Range of G4C2 repeats Small allele 2–11 2–8 2–8 2–10 2–5
Larger allele 35, exp 2–22 2–19 exp 2–12
Abbreviation is as follows: exp, expansion.Toronto according to established criteria.23–25 Expansion
carriers were defined by the previously suggested 30-repeat
cutoff.1,2 DNA from blood was available for 37 unrelated
ALS expansion carriers (mainly identified in our previous
study7) and 140 noncarriers (64 ALS cases and 76 controls
>65 years old). Sample characteristics are presented in
Table 1. The clinical parameters between ALS expansion
carriers and noncarriers are similar, except that carriers
have an earlier age of onset (p ¼ 0.04) and higher percent-
age of familial cases (p¼ 23 106), which is a known asso-
ciation.4 In addition, we investigated blood DNA from
available family members of seven ALS probands with
the expansion (including four simplex cases) and three
previously reported7 carriers of intermediate alleles (24,
32, 39 repeats) diagnosed with Parkinson disease (MIM
168600). DNA was also extracted from blood, frontal cor-
tex, and cervical spinal cord for seven autopsy-confirmed
expansion carriers, as well as from frontal cortex of 14
controls.
To assess the level of methylation we developed two
assays. The basis of the methylation-sensitive restriction
enzyme assay was adapted from previous reports26,27 (the
experimental principle is shown in Figure S2). In brief,
100 ng of DNA was digested overnight at 37C with 1 U
methylation-sensitive restriction enzyme (HhaI, HpaII, or
HpyCH4IV, New England Biolabs), followed by 10 min
inactivation at 95C. The enzyme digests unmethylated
DNA, and therefore the following PCR would produce an
amplification product only for methylated DNA. As an in-
ternal control, a duplicate reaction for each DNA sample
was prepared without the enzyme. The digested and undi-
gested DNA was amplified in parallel (Tm ¼ 60.5C) (Table
S1). PCR products (1.5 ml) were resolved on a 1.5% agarose
gel. To quantify the band intensity, black/white inverted
gel images were analyzed by the Gel Analysis tool in Image
J, and the observed methylation (OM) ratio was calculated
based on the band intensities (PCR from digested DNAO
PCR from undigested DNA).982 The American Journal of Human Genetics 92, 981–989, June 6, 2The direct bisulfite sequencing assay was adapted from
previous reports.19,28,29 It is based on the conversion of un-
methylated C to T by bisulfite treatment, while methylated
C remain unchanged. Bisulfite treatment was performed
with 100 ng of DNA by the Imprint DNA Modification
kit (Sigma). The investigated region is shown in Figure S3.
After conversion, the region 50 of the G4C2 repeat was
amplified by a seminested PCR (Table S1). Bisulfite-treated
DNA (2 ml) was amplified by FastStart PCR Master Mix
(Roche) by touchdown PCR (for primers BSP_1F, BSP_1R:
Tm from 68C to 58C at a rate of 1C/cycle and fixed
at 58C for 30 cycles; for primers BSP_2F, BSP_2R: Tm
from 67C to 57C at a rate of 1C/cycle and fixed at
57C for 20 cycles; 3 min extension for each cycle).
Methylation was detected by direct inspection of
sequencing chromatograms and an integrated tool within
Mutation Surveyor version 4.0 (Softgenetics). Only sam-
ples with >95% conversion rate of non-CpG C were
included in the analyses. To avoid quantification errors
caused by relative peak height measurements at each
CpG, broad categories were used to score methylation
level: unmethylated CpG (T peak) or methylated CpG
(T/C double peaks). Of note, ‘‘C peak only’’ (indicating
100% methylation) was not observed in any sample. For
each sample we obtained the total number of methylated
CpG sites detected in the inspected region.
A linear regression analysis was performed between the
OM ratio (HhaI assay) and number of methylated CpG
sites (bisulfite sequencing assay) to calculate the correla-
tion between the assays. A nonlinear regression analysis
was used to evaluate the correlation between methylation
level and disease duration. The goodness of fit measure (R2)
was used to quantify these correlations. The p value was
calculated by ANOVA to determine the significance of R2.
Pearson’s or Spearman’s correlation coefficients were used
to measure the correlation between independent variables:
repeat size (<50 repeats), age, and methylation level. The
nonparametric Mann-Whitney U test was used to compare013
Figure 1. HhaI Assay
(A) A schematic presentation of the
genomic region around the G4C2 repeat.
Two predicted CpG islands located in
the sequences flanking the repeat were
covered by three fragments.
(B) DNA undigested and digested with
HhaI was amplified for all three fragments
and the resulting band intensity quanti-
fied. Only fragment #1 shows differential
methylation between expansion carriers
and noncarriers.
(C) Samples with intermediate size alleles
(24–43 repeats) were not methylated up-
stream of the G4C2 repeat (fragment #1).
(D) Representative gel analysis of 12 ALS
expansion carriers, 12 ALS noncarriers,
and 12 controls (a higher methylation
level was observed in expansion carriers
versus noncarriers).continuous variables between two groups. The two-sided
Pearson c2 test or Fisher’s exact test (when expected value
<5) were used to compare categorical variables. All ana-
lyses were performed with SPSS (v.20).
By using the UCSC database, we detected two predicted
CpG islands immediately flanking the G4C2 repeat (Fig-
ure S1), which contain restriction sites for three methyl-
ation-sensitive enzymes (HhaI, HpaII, and HpyCH4IV).
To assess the sensitivity of these enzymes for methylation
detection, we used a premixed calibration standard DNA
(EpigenDx) consisting of a low-methylated DNA (<5%
methylation), a high-methylated DNA (>85% methyl-
ation), and a mixture series of both. The region 50 of the
G4C2 repeat (fragment #1) has two HhaI, one HpaII, and
three HpyCH4IV sites (Figure S4A). Analysis of fragment
#1 revealed that the HhaI assay is the most sensitive,
because it is able to detect methylation in a mixture con-
taining only 5% high-methylated DNA, whereas the other
two enzymes start to detect methylation from 25% to 50%
(Figure S4B). No methylation was observed for the DNA of
a randomly selected nonexpansion carrier (Figure S4B). By
measuring band intensity (four replicates), we obtained a
standard curve with R2 ¼ 0.96, indicating the reliability
of the quantification by the HhaI assay (Figure S4C). There-
fore, the following case-control study was conducted with
the HhaI assay.
The same calibration DNA standards were used to assess
the efficiency of the bisulfite sequencing assay. All non-
CpG C were successfully converted to T (Figure S4D). As
expected, only a few methylated C were detected in the
low-methylated standard, and the assay was able to detectThe American Journal of Humamethylation of all CpG sites, even in
the mixture with only 5% high-meth-
ylated DNA.
CpG islands on both sides of the
G4C2 repeat were analyzed by the
HhaI assay (Figure 1A). The region 50
(but not 30) of the repeat revealed
evidence of hypermethylation in expansion carriers (Fig-
ure 1B). The bisulfite sequencing assay also revealed evi-
dence of hypermethylation at the 50 region (as presented
below) but not the 30 region, which was evaluated in the
pilot ALS cohort of 32 expansion carriers and 16 noncar-
riers (data not shown). A similar methylation pattern was
reported for Friedreich ataxia15 and myotonic dystro-
phy.19 It was suggested that an expanded repeat could
act as a barrier inhibiting the spread of methylation down-
stream;15 however, the underlying mechanism is not well
understood. Notably, the G4C2 repeat expansion itself
could also be considered part of the CpG island and may
be methylated as well, but currently available technologies
do not allow the large expansion to be amplified by PCR or
thoroughly sequenced.
Next, methylation of the CpG island 50 of the G4C2
repeat was assessed by both assays in the entire data set of
177 unrelated individuals. The OM ratio of the HhaI assay
was significantly higher in the group of 37 ALS expansion
carriers (mean5 SD ¼ 0.525 0.40) versus 64 ALS noncar-
riers (mean5 SD¼ 0.175 0.09, Mann-Whitney U test p<
0.0001) or versus 76 controls (mean5 SD ¼ 0.135 0.07,
Mann-Whitney U test p < 0.0001). Almost all samples
without an expansion allele (138 out of 140) had an OM
ratio below 0.3, which represents the methylation level of
the low-methylated DNA standard (<5% methylation) in
the HhaI assay standard curve. In contrast, 25 of 37 ALS ex-
pansion carriers had a ratio>0.3. A representative gel image
of 12 samples from each group is shown in Figure 1D.
The bisulfite sequencing assay revealed the methylation
status 50 of the G4C2 repeat beyond the two CpG sitesn Genetics 92, 981–989, June 6, 2013 983
Figure 2. Correlation between HhaI
Assay and the Bisulfite Sequencing Assay
(A) Representative chromatograms of a
sequence containing seven CpG sites for
an expansion carrier and a noncarrier.
(B) A scatter plot of the observed methyl-
ation ratio (HhaI assay) and number
of methylated CpG sites (bisulfite
sequencing) revealed a significant correla-
tion between the two assays with blood
DNA.recognized by the HhaI assay. A total of 26 CpG sites were
assessed (Figure S3). A representative sequence chromato-
gram is shown in Figure 2A. In the nonexpansion group,
97% of samples (n ¼ 136) were unmethylated (number
of methylated CpG sites ¼ 0). In contrast, 73% of expan-
sion carriers (n ¼ 27) had a number of methylated CpG
sites R1, and methylation was detected at each of the 26
CpG sites (Figure S5A). We categorized the different
methylation levels based on the maximum number of
methylated CpG observed in controls: 0, no methylation;
1–3, low methylation; and 4–26, high methylation
(Table 2). In agreement with the HhaI assay, a significant
difference in methylation level between the expansion
and nonexpansion groups was observed (p < 0.0001). No
difference was found between the two nonexpansion
groups (control versus ALS, p ¼ 0.625).Table 2. Methylation Level of Blood DNA from ALS Expansion Carriers, ALS Nonexpansion Car
Methylation Level (Number of Methylated CpG)
ALS Exp ALS Nonexp
N Frequency N
No methylation (0) 10 0.27 63
Low methylation (1–3) 12 0.32 1
High methylation (4–26) 15 0.41 0
Total 37 64
pa: compared to ALS exp group <0.0001
pa: compared to ALS nonexp group
Abbreviation is as follows: exp, expansion.
a2-sided Pearson c2 test was used, df ¼ 2. Fisher’s exact test was used (when expected value < 5).
984 The American Journal of Human Genetics 92, 981–989, June 6, 2013A scatter plot of the OM ratio
against the number of methylated
CpG sites revealed a significant
correlation between the two assays
(p < 0.0001) (Figure 2B). Bisulfite
sequencing analysis of the 26 CpG
sites revealed that the two CpG sites
recognized by the HhaI assay (CpG2
and CpG8) are among the most
frequently methylated sites in expan-
sion carriers (70% and 30%, respec-
tively), which is the basis of the
strong correlation between the assays
(Figure S5A).Notably, neither assay identified methylation in carriers
with intermediate alleles (24, 32, 39, or 43 repeats;
Figure 1C). Individuals without an expansion had a wide
range of normal alleles (2–22 repeats) (Table 1), all of which
had a low methylation level (methylated CpG sites < 3).
Finally, the number of methylated CpG sites in expansion
carriers and the size of their normal allele (2–11 repeats)
were not correlated (Spearman’s correlation coefficient ¼
0.258, p ¼ 0.124), indicating that the normal allele does
not contribute to the methylation profile of expansion
carriers.
The level of methylation 50 of the G4C2 repeat did not
correlate with age at time of examination (range: 39–80
years old; Spearman’s correlation coefficient ¼ 0.015,
p ¼ 0.931) or age of onset (range: 37–78 years old; Spear-
man’s correlation coefficient¼ 0.041, p¼ 0.814). However,riers, and Controls
Control
Frequency N Frequency
0.98 73 0.96
0.02 3 0.04
0.00 0 0.00
76
<0.0001
0.625
Table 3. Methylation Levels within the ALS Pedigrees
Pedigree N
Number of
Generations
with Exp
Observed Methylation Ratio
(HhaI Assay)
Number of Methylated CpG Sites of Each Pedigree
(Bisulfite Sequencing)
Mean 5 SD Mean 5 SD Methylation Level
Expansion Carriers
ped 1 4 1 0.37 5 0.21 1 5 1.2 low
ped 3 2 2 0.44 5 0.02 2 5 1.0 low
ped 6 4 2 0.83 5 0.13 13 5 3.6 high
1 (43 repeats) 1 0.17 0 no
ped 8 2 1 0.38 5 0.05 4 5 1.5 high
ped 13 1 1 0.9 13 high
ped 16 2 1 1.05 5 0.00 21 5 4.0 high
ped 17 2 1 0.72 5 0.02 15 5 7.5 high
Nonexpansion Carriers
All pedigrees 8 0.21 5 0.06 05 0.6 no
Abbreviation is as follows: exp, expansion.it was inversely associated with disease duration (n ¼ 24;
OM: R2 ¼ 0.388, p ¼ 0.001; number of methylated CpG
sites: R2 ¼ 0.303, p ¼ 0.005). Moreover, methylation was
also significantly associated with familial ALS (HhaI assay:
Mann-Whitney U test p ¼ 0.009; bisulfite sequencing
assay: Mann-Whitney U test p ¼ 0.026 and Pearson c2
p ¼ 0.036) but not with site of onset or diagnosis subcate-
gory (ALS versus ALS-FTD). The study of seven families
indicated that high methylation level segregates with the
expansion (Table 3, Figure 3). The number of methylated
CpG sites observed in expansion carriers was similar
within each pedigree, but variable between families. High
methylation levels were not observed in family members
without an expansion, in contrast to their relatives with
an expansion. For instance, in family PED 6 (Figure 3), in-
dividual #8259 (noncarrier, III-2) shares a 7-repeat allele
with sibling #8261 (carrier, III-4) and inherited an 8-repeat
allele from their parent #7387 (carrier, II-3) but does not
have a high methylation level.
Differential methylation across different tissues is
known to be common in mammals,30 although concor-
dance of methylation level across different tissues was
seen in the GAA expansion causing Friedreich ataxia.15
According to GENEVESTIGATOR, C9orf72 is robustly ex-
pressed in different human tissues, including blood and
brain. Therefore, we evaluated the methylation level in
blood, frontal cortex, and cervical spinal cord available
from seven individuals with ALS. The degree of methyl-
ation in frontal cortex of these individuals was higher
than in DNA from control brain samples (n ¼ 14) (Table
S2). Importantly, methylation levels for DNA isolated
from the three tissues for the same person were within a
similar range by both assays (Figures S5B and S6). Signifi-
cant correlation was observed between the different tissuesThe Amin almost all pairwise combinations (Table S3). However,
this observation remains to be validated in a larger sample
set.
Available RNA samples (n ¼ 8) were analyzed by an in-
ventoried TaqMan gene expression assay targeting all
known C9orf72 transcripts (Figure 4). Total blood RNA
was extracted with the RNeasy Mini Kit (QIAGEN) and
reverse transcribed to cDNA by the AffinityScript Multiple
Temperature cDNA Synthesis Kit (Agilent Technologies).
RNA integrity was checked on an Agilent 2100 Bioanalyzer
(only samples with RIN > 7 were used). Real-time PCR
was performed in triplicate for HPRT1 (MIM 308000)
(Hs99999909_m1), UBC (MIM 191340) (Hs00824723_
m1), B2M (MIM 109700) (Hs99999907_m1), and C9orf72
(Hs00376619_m1) (Applied Biosystems) and analyzed on
an ABI Prism 7500 system (Life Technologies). Relative
quantification was determined by qBASE PLUS software
(Biogazelle) with the ddCt method after normalization to
HPRT1, UBC, and B2M. Carriers of a hypermethylated
allele with >50 repeats (n ¼ 4) have reduced expression
compared to noncarriers (n ¼ 3). Notably, the carrier of
an unmethylated allele with 43 repeats (ID#8520, II-4 in
PED 6, Figure 3) has an expression level similar to noncar-
riers. These data support the hypothesis that hypermethy-
lation may underlie the reduced C9orf72 expression.
It is intriguing that a high methylation level was signif-
icantly associated with familial ALS, whereas half of the
expansion carriers (mainly sporadic cases) showed either
low or no methylation. The repeat size itself could be an
explanation for the wide range of methylation levels
among expansion carriers. Indeed, a direct correlation
between CpG methylation and repeat size was observed
in Friedreich ataxia,31 in which the degree of methylation
gradually increased along with the number of GAAerican Journal of Human Genetics 92, 981–989, June 6, 2013 985
Figure 3. Methylation Results in Three
Representative Families of Probands who
Carry the C9orf72 Expansion
All available family members were studied
to compare methylation levels. Individual
ID and C9orf72 genotype are shown
beneath the corresponding diamond.
Arabic numbers indicate the repeat num-
ber and ‘‘exp’’ represents the expansion
allele. Age at the time of examination is
shown in the upper right corner. Age of
onset is indicated above the ID number.
Gender of the family members is masked
to protect confidentiality. Black/white in-
verted gel images from the HhaI assay
are shown below the genotype. The indi-
vidual number of methylated CpG sites is
shown on the right side of the gel image
beneath ‘‘BSP,’’ which stands for bisulfite
sequencing PCR.repeats (from ~200 repeats to ~1,200 repeats32). However,
assessment of the C9orf72 repeat number is technically
challenging because of the high GC content and possible
somatic instability. Repeat-primed PCR can only resolve
the precise size for expansions of up to 50 repeats;
although in a few published cases, the size of the expan-
sion was estimated by Southern blot (up to 3,400 repeats
in blood33 and 700–2,000 repeats in lymphoblasts1,34).
Expansions on such a scale are much larger than the cur-
rent cutoff for pathologic alleles (30 repeats). Hence, the
repeat size is likely to be highly variable between expan-
sion carriers, and whether these alleles have the same
pathologic significance has to be carefully assessed in the
future. Notably, we did not detect methylation 50 of the
repeat for either normal (2–22 repeats) or intermediate
(up to 43 repeats) alleles, bringing to question the 30-
repeat cutoff for pathological alleles. Future studies have
to establish whether methylation level indeed mirrors
repeat size, because differences in repeat size and methyl-
ation degree could be players in the highly heterogeneous
clinical and neuropathological presentations observed in
expansion carriers.35–37
Our initial results from seven families indicate that the
level of methylation could depend on repeat size. Expan-
sion carriers identified in each kindred are mostly from986 The American Journal of Human Genetics 92, 981–989, June 6, 2013the same generation (Table 3,
Figure 3), and the size of the expan-
sion is likely to bemore similar within
the same pedigree than between
different families. The observed de-
gree of methylation reflected a similar
tendency: high variability was ob-
served between families, but a similar
degree of methylation was detected
among members of the same family
with the exception of the asymptom-
atic individual ID#8520 (II-4 in PED
6, Figure 3) with an unmethylatedintermediate allele (43 repeats). In contrast, the rest of
the expansion carriers in PED6 carry a highly methylated
expanded allele (>50 repeats). Gene expression analysis
of C9orf72 further separates this 43-repeat carrier from
family members with larger expansions (>50 repeats) by
displaying a normal level of C9orf72 expression (Figure 4).
So far, this pedigree is the only example that methylation
level could reflect repeat size, and it would be important
to evaluate more carriers of intermediate alleles. Further-
more, the significant association of hypermethylation
with familial ALS could also indicate a correlation with
repeat size. In repeat expansion diseases, longer alleles
are more likely to undergo an expansion mutation than
shorter ones,38 so familial cases could have an increased
probability for their repeat to expand further and carry
longer alleles than sporadic cases. In Friedreich ataxia
and Huntington disease (MIM 143100), repeat length
is known to relate to disease severity and age of
onset.15,32,38–40 A hallmark ofmost repeat expansion disor-
ders is genetic anticipation that reflects the tendency for
larger expansions in subsequent generations. In C9orf72-
linked disease, genetic anticipation was also suggested by
a few studies.4,7
In conclusion, we conducted an epigenetic investigation
into the functional consequence of the C9orf72 repeat
Figure 4. Relative Quantification of C9orf72 mRNA
All transcripts were detected by an inventoried TaqMan gene
expression assay (Hs00376619_m1) and relative expression was
obtained by normalizing to three reference genes (HPRT1, UBC,
and B2M). Error bars represent the standard error of the triplicate
reactions. Expansion carriers were shown to have reduced
C9orf72 expression compared nonexpansion carriers, whereas ID
#8520 with 43 repeats had a normal C9orf72mRNA level. Notably,
gene expression is inversely related to methylation level. Number
of methylated CpG site is shown beneath each sample. ‘‘BSP’’
stands for bisulfite sequencing PCR.expansion in ALS. Importantly, the hypermethylation was
expansion specific in our data set, because it was not
detected in any noncarriers. Moreover, a higher degree of
methylation correlated with shorter disease duration, indi-
cating that it may be associated with increased ALS
severity. However, future replication studies would require
the analysis of independent larger data sets to validate our
findings. The obtained methylation data may be the basis
for a future diagnostic approach to C9orf72 disease. By
carefully comparing the CpG methylation profile between
expansion carriers, future studies could determine
whether disease phenotype is dependent on the degree
or sites of methylation. For instance, it is tempting to
speculate that the degree of methylation could be an
important factor in modifying disease presentation (e.g.,
ALS versus FTLD).Supplemental Data
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